3 5 1 3 uc 12673 mrsa (ATCC)
ATCC is a verified supplier 
ATCC manufactures this product 
90
Structured Review
ATCC
3 5 1 3 uc 12673 mrsa
3 5 1 3 Uc 12673 Mrsa, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/3+5+1+3+uc+12673+mrsa/Nocardioides+nitrophenolicus+Yoon+et+al/10__1128_slash_aac__40__4__839-189-86-76
Average 90 stars, based on 18 article reviews
3 5 1 3 Uc 12673 Mrsa, supplied by ATCC, used in various techniques. Bioz Stars score: 90/100, based on 18 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/3+5+1+3+uc+12673+mrsa/Nocardioides+nitrophenolicus+Yoon+et+al/10__1128_slash_aac__40__4__839-189-86-76
Average 90 stars, based on 18 article reviews
3 5 1 3 uc 12673 mrsa - by Bioz Stars,
2026-10
90/100 stars
Images
Related Articles
Comparison:Article Title: In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents Article Snippet: Oxazolidinones make up a relatively new class of antimicrobial agents which possess a unique mechanism of bacterial protein synthesis inhibition.. U-100592 {(S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide} and U-100766 {(S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide} are novel oxazolidinone analogs from a directed chemical modification program.. MICs were determined for a variety of bacterial clinical isolates; the respective MICs of U-100592 and U-100766 at which 90% of isolates are inhibited were as follows: methicillin-susceptible Staphylococcus aureus, 4 and 4 mg/ml; methicillin-resistant S. aureus, 4 and 4 mg/ml; methicillin-susceptible Staphylococcus epidermidis, 2 and 2 mg/ml; methicillin-resistant S. epidermidis, 1 and 2 mg/ml; Enterococcus faecalis, 2 and 4 mg/ml; Enterococcus faecium, 2 and 4 mg/ml; Streptococcus pyogenes, 1 and 2 mg/ml; Streptococcus pneumoniae, 0.50 and 1 mg/ml; Corynebacterium spp., 0.50 and 0.50 mg/ml;Moraxella catarrhalis, 4 and 4 mg/ml; Listeria monocytogenes, 8 and 2 mg/ml; and Bacteroides fragilis, 16 and 4 mg/ml. Control:Article Title: In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents Article Snippet: Oxazolidinones make up a relatively new class of antimicrobial agents which possess a unique mechanism of bacterial protein synthesis inhibition.. U-100592 {(S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide} and U-100766 {(S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide} are novel oxazolidinone analogs from a directed chemical modification program.. MICs were determined for a variety of bacterial clinical isolates; the respective MICs of U-100592 and U-100766 at which 90% of isolates are inhibited were as follows: methicillin-susceptible Staphylococcus aureus, 4 and 4 mg/ml; methicillin-resistant S. aureus, 4 and 4 mg/ml; methicillin-susceptible Staphylococcus epidermidis, 2 and 2 mg/ml; methicillin-resistant S. epidermidis, 1 and 2 mg/ml; Enterococcus faecalis, 2 and 4 mg/ml; Enterococcus faecium, 2 and 4 mg/ml; Streptococcus pyogenes, 1 and 2 mg/ml; Streptococcus pneumoniae, 0.50 and 1 mg/ml; Corynebacterium spp., 0.50 and 0.50 mg/ml;Moraxella catarrhalis, 4 and 4 mg/ml; Listeria monocytogenes, 8 and 2 mg/ml; and Bacteroides fragilis, 16 and 4 mg/ml. Bacteria:Article Title: In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents Article Snippet: Oxazolidinones make up a relatively new class of antimicrobial agents which possess a unique mechanism of bacterial protein synthesis inhibition.. U-100592 {(S)-N-[[3-[3-fluoro-4-[4-(hydroxyacetyl)-1-piperazinyl]phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide} and U-100766 {(S)-N-[[3-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-5-oxazolidinyl]methyl]-acetamide} are novel oxazolidinone analogs from a directed chemical modification program.. MICs were determined for a variety of bacterial clinical isolates; the respective MICs of U-100592 and U-100766 at which 90% of isolates are inhibited were as follows: methicillin-susceptible Staphylococcus aureus, 4 and 4 mg/ml; methicillin-resistant S. aureus, 4 and 4 mg/ml; methicillin-susceptible Staphylococcus epidermidis, 2 and 2 mg/ml; methicillin-resistant S. epidermidis, 1 and 2 mg/ml; Enterococcus faecalis, 2 and 4 mg/ml; Enterococcus faecium, 2 and 4 mg/ml; Streptococcus pyogenes, 1 and 2 mg/ml; Streptococcus pneumoniae, 0.50 and 1 mg/ml; Corynebacterium spp., 0.50 and 0.50 mg/ml;Moraxella catarrhalis, 4 and 4 mg/ml; Listeria monocytogenes, 8 and 2 mg/ml; and Bacteroides fragilis, 16 and 4 mg/ml. |